- Home
- VERU vs PAVS Comparison
VERU vs PAVS Comparison
Compare VERU & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- PAVS
- Stock Information
- Founded
- VERU 1971
- PAVS 2004
- Country
- VERU United States
- PAVS United States
- Employees
- VERU N/A
- PAVS N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- VERU Health Care
- PAVS Health Care
- Exchange
- VERU Nasdaq
- PAVS Nasdaq
- Market Cap
- VERU 76.9M
- PAVS 89.6M
- IPO Year
- VERU 1990
- PAVS 2019
- Fundamental
- Price
- VERU $0.54
- PAVS $1.34
- Analyst Decision
- VERU Strong Buy
- PAVS
- Analyst Count
- VERU 3
- PAVS 0
- Target Price
- VERU $4.33
- PAVS N/A
- AVG Volume (30 Days)
- VERU 2.0M
- PAVS 17.2K
- Earning Date
- VERU 05-07-2025
- PAVS 01-01-0001
- Dividend Yield
- VERU N/A
- PAVS N/A
- EPS Growth
- VERU N/A
- PAVS N/A
- EPS
- VERU N/A
- PAVS N/A
- Revenue
- VERU $16,886,419.00
- PAVS $6,613,273.00
- Revenue This Year
- VERU N/A
- PAVS N/A
- Revenue Next Year
- VERU N/A
- PAVS N/A
- P/E Ratio
- VERU N/A
- PAVS N/A
- Revenue Growth
- VERU 22.46
- PAVS N/A
- 52 Week Low
- VERU $0.45
- PAVS $0.32
- 52 Week High
- VERU $1.75
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- VERU 49.37
- PAVS 47.84
- Support Level
- VERU $0.51
- PAVS $1.28
- Resistance Level
- VERU $0.56
- PAVS $1.40
- Average True Range (ATR)
- VERU 0.04
- PAVS 0.06
- MACD
- VERU 0.00
- PAVS -0.00
- Stochastic Oscillator
- VERU 38.00
- PAVS 70.14
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.